0001799788 false 0001799788 2021-12-15 2021-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) December 15, 2021


Greenwich LifeSciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-39555   20-5473709

(State or other jurisdiction

of incorporation)



File Number)


(I. R. S. Employer

Identification No.)


3992 Bluebonnet Dr, Building 14

Stafford, TX 77477

(Address of principal executive offices, including ZIP code)


(832) 819-3232

(Registrant’s telephone number, including area code)


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   GLSI   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 5.07 Submission of Matters to a Vote of Security Holders


On December 15, 2021, Greenwich LifeSciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 10,540,382 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on October 19, 2021 are as follows:


Proposal 1. All of the five (5) nominees for director were elected to serve until the 2022 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five (5) directors was as follows:


Directors  For   Against   Abstain   Broker Non Vote 
David McWilliams   9,368,038    0    603,421    568,923 
Snehal S. Patel   9,866,004    0    105,455    568,923 
Eric Rothe   9,385,674    0    585,785    568,923 
F. Joseph Daugherty, M.D.   9,817,393    0    154,066    568,923 
Kenneth Hallock   9,689,781    0    281,678    568,923 


Proposal 2. The appointment of Malone Bailey, LLP as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2021 was ratified and approved by the stockholders by the votes set forth in the table below:


For   Against   Abstain   Broker Non Vote 
 10,523,113    6,200    11,069    0 






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Greenwich LifeSciences, Inc.
Date: December 15, 2021 By: /s/ Snehal Patel
    Snehal Patel
    Chief Executive Officer